6757-36-4

Upstream product

• 2905-60-4 2,3-dichlorobenzoyl chloride 
• 33577-16-1 methyl methylsulfinylmethyl sulfide 
• 64-17-5 ethanol 
• 10236-60-9 (2,3-dichlorophenyl)acetic acid 

Downstream Products

• 2012-77-3 2-(2,3-dichlorophenyl)propanoic acid 

Relevant academic research and scientific papers

2-(Halogenated Phenyl) acetamides and propanamides as potent TRPV1 antagonists

A series consisting of 117 2-(halogenated phenyl) acetamide and propanamide analogs were investigated as TRPV1 antagonists. The structure–activity analysis targeting their three pharmacophoric regions indicated that halogenated phenyl A-region analogs exhibited a broad functional profile ranging from agonism to antagonism. Among the compounds, antagonists 28 and 92 exhibited potent antagonism toward capsaicin for hTRPV1 with Ki[CAP] = 2.6 and 6.9 nM, respectively. Further, antagonist 92 displayed promising analgesic activity in vivo in both phases of the formalin mouse pain model. A molecular modeling study of 92 indicated that the two fluoro groups in the A-region made hydrophobic interactions with the receptor.

Alpha,beta-unsaturated esters and acids by stereoselective dehydration

There are provided by the present invention certain pyrazole based CCK-1 receptor modulators which have the general formula: wherein Ar is an aromatic or heteroaromatic group, X is a hydrocarbon linker, Y is a bond or hydrocarbon linker and R1, R2, R3, R4 and R5 are certain organic substituents, methods for making the same, and stereoselective dehydration methods for generally making α,β-unsaturated esters, acids and their derivatives.

CCK-1 RECEPTOR MODULATORS

There are provided by the present invention certain pyrazole based CCK-1 receptor modulators which have the general formula: (I) wherein Ar is an aromatic or heteroaromatic group, X is a hydrocarbon linker, Y is a bond or hydrocarbon linker and R1, R2, R3, R4 and R5 are certain organic substituents, and methods of making the same.

CCK-1 RECEPTOR MODULATORS

There are provided by the present invention certain pyrazole based CCK-1 receptor modulators.

Reactions of cationic (η6-chloroarene) complexes of iron and ruthenium with some O-silyl and C-silyl compounds

The introduction of an alylcarbonyl side chain into the aromatic ring of some chloro-substituted benzenes has been achieved under mild conditions by the Yanovsky-type reaction of (η6-chloroarene)(η5-cyclopentadienyl) cationic complex

Pharmacologically active CNS compound

The invention provides a series of compounds of formula (I) and salts thereof, wherein for example,R1 and R2, which may be the same or different each represent -NR13R14 where R13 and R14 may each independently represent hydrogen or alkyl or, taken together with the nitrogen atom to which they are attached form a heterocyclic ring, optionally substituted by one or more alkyl or arylalkyl groups and optionally containing a further heteroatom;, R3 is hydrogen, haloalkyl, alkoxymethyl or alkyl;, R4 is hydrogen, nitro or halo;, R5 is hydrogen or halo;, R6 is hydrogen, halo, nitro, amino, alkylamino or dialkylamino;, R7 is hydrogen or halo;, R8 is hydrogen or halo; The compounds may be used for the treatment or prophylaxis of a neurodegenerative or other neurological disorder of the CNS, the aetiology or which includes excessive release of the neurotransmitter glutamate.